Home / Learn / Precision Medicine / Treatment / Immunotherapy / Resource Detail

irAE Workup Guidelines

June 26, 2024

Managing immune-related adverse events among patients who have received immune checkpoint inhibitors (ICI) can present many challenges for the multidisciplinary care team. Not only can irAEs be difficult to distinguish from other conditions, but knowing how and when to admit a patient, treat symptoms, or withhold ICI therapy can be difficult to navigate. However, in recent years, many organizations have published formal recommendations, or workup guidelines, for managing irAEs, including ASCO, ESMO, NCCN, and SITC.

The following can be used as a directory for the current irAE workup guidelines. Click to expand the organ system of interest to display the common irAEs for which guidelines are available, with details of where to find the condition-specific information in each set of guidelines.

ASCO GUIDELINES (AS OF 2018):
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-1768 doi.org/10.1200/JCO.2017.77.6385

ESMO GUIDELINES (AS OF 2017):
Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(S4): i119-i142. doi.org/10.1093/annonc/mdx225

ESMO GUIDELINES CORRECTION (AS OF 2018):
Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(S4): iv264-iv266. doi.org/10.1093/annonc/mdy162

NCCN GUIDELINES (AS OF 2019):
Available on the NCCN website under NCCN Guidelines for Supportive Care, listed as Management of Immunotherapy-Related Toxicities. Login required; registration is free. https://www.nccn.org/

SITC GUIDELINES (AS OF 2017):
Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J ImmunoTher Cancer. 2017;5(95). DOI 10.1186/s40425-017-0300-z

Cardiovascular

Dermatologic

Bulbous Dermatoses

ASCO Guidelines, see pages 1721-1722, Table 1
NCCN Guidelines, see pages 260, 271-272

Pruritis

NCCN Guidelines, see pages 259, 271-272
SITC Guidelines, see pages 6, 7 (Table 3)

Rash/Dermatitis

ASCO Guidelines, see pages 1716, 1720-1721, Table 1
ESMO Guidelines, see pages iv122-iv123, Figure 3, Table 2
NCCN Guidelines, see pages 258, 271-272
SITC Guidelines, see pages 6, 7 (Table 3), 16

Severe Cutaneous Adverse Reactions (SCARS) (including SJS, TEN, Acute Generalized Exanthematous Pustulosis, and DRESS/DIHS)

ASCO Guidelines, see pages 1722-1723, Table 1
NCCN Guidelines, see pages 260, 271-272

Endocrine

Asymptomatic/Subclinical Hypothyroidism

NCCN Guidelines, see pages 267, 275-277

Central Hypothyroidism

NCCN Guidelines, see pages 269, 275-277

Hyperthyroidism

ASCO Guidelines, see page 1734, Table 4
SITC Guidelines, see page 10 (Table 3)

Hypophysitis

ASCO Guidelines, see page 1734, Table 4
ESMO Guidelines, see pages iv124-iv126, Figure 6, Table 2
NCCN Guidelines, see pages 269, 275-277
SITC Guidelines, see pages 9 (Table 3), 18

Primary Adrenal Insufficiency

ASCO Guidelines, see page 1734, Table 4
NCCN Guidelines, see pages 268, 275-277

Primary Hypothyroidism

ASCO Guidelines, see pages 1730, 1734, Table 4
ESMO Guidelines, see pages iv123-iv124, Figure 5, Table 2
NCCN Guidelines, see pages 267, 275-277
SITC Guidelines, see pages 9 (Table 3), 18-19

Thyrotoxicosis

NCCN Guidelines, see pages 267, 275-277
SITC Guidelines, see page 19

Gastrointestinal

Hematologic

Acquired Hemophilia

ASCO Guidelines, see page 1755, Table 8

Acquired Thrombotic Thrombocytopenic Purpura (TTP)

ASCO Guidelines, see page 1753, Table 8

Aplastic Anemia

ASCO Guidelines, see pages 1753-1754, Table 8

Autoimmune Hemolytic Anemia

ASCO Guidelines, see pages 1748, 1752-1753, Table 8
SITC Guidelines, see pages 13 (Table 3), 23

Hemolytic Uremic Syndrome

ASCO Guidelines, see page 1753, Table 8

Immune Thrombocytopenia

ASCO Guidelines, see pages 1754-1755, Table 8
SITC Guidelines, see pages 13 (Table 3), 23

Lymphopenia

ASCO Guidelines, see page 1754, Table 8

Hepatic

Musculoskeletal

Inflammatory Arthritis

ASCO Guidelines, see pages 1736, 1739, Table 5
ESMO Guidelines, see page iv133, Figure 13, Table 2
NCCN Guidelines, see pages 280, 282-283
SITC Guidelines, see pages 11-12 (Table 3), 20-22

Myositis

ASCO Guidelines, see page 1739, Table 5
NCCN Guidelines, see pages 281-283

Polymyalgia-like Syndrome

ASCO Guidelines, see pages 1740-1741, Table 5

Nervous System

Aseptic Meningitis

ASCO Guidelines, see page 1747, Table 7
ESMO Guidelines, see page iv133, Figure 12, Table 2
NCCN Guidelines, see pages 277, 279-280

Autonomic Neuropathy

ASCO Guidelines, see page 1747, Table 7

Encephalitis

ASCO Guidelines, see pages 1747-1748, Table 7
ESMO Guidelines, see page iv133, Figure 12, Table 2
NCCN Guidelines, see pages 277, 279-280

Encephalopathy/PRES

SITC Guidelines, see page 14 (Table 3), 24

Guillain Barré Syndrome

ASCO Guidelines, see page 1743, 1746, Table 7
ESMO Guidelines, see page iv133, Figure 11, Table 2
NCCN Guidelines, see pages 275, 279-280

Myasthenia Gravis

ASCO Guidelines, see page 1743, Table 7
ESMO Guidelines, see page iv133, Figure 11, Table 2
NCCN Guidelines, see pages 274, 279-280

Peripheral Neuropathy

ASCO Guidelines, see pages 1746-1747, Table 7
NCCN Guidelines, see pages 276, 279-280
SITC Guidelines, see page 14 (Table 3), 24

Transverse Myelitis

ASCO Guidelines, see page 1748, Table 7
ESMO Guidelines, see page iv133, Figure 12, Table 2
NCCN Guidelines, see pages 278-280

Ocular

Blepharitis

ASCO Guidelines, see page 1761
SITC Guidelines, sees page 16 (Table 3), 24-25

Episcleritis

ASCO Guidelines, see page 1759, Table 10
NCCN Guidelines, see page 273
SITC Guidelines, see pages 15-16 (Table 3), 24-25

Uveitis/Iritris

ASCO Guidelines, see page 1759, Table 10
ESMO Guidelines, see page iv133
NCCN Guidelines, see pages 273, 278-279
SITC Guidelines, see pages 15 (Table 3), 24-25

Pancreatic

Pulmonary

Renal

Additional Resources

Symptoms & Grading: National Cancer Institute. (2017). Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Available here.

Routine Monitoring Recommendations:

NCCN Guidelines, see page 257

Industry Toxicity Management Recommendations:

ACCC IO Wallet Card: Equip IO patients with a medical wallet card that includes the warning signs of common irAEs. Available here.

Share

In This Section

irAE Workup Guidelines